Galderma, a Swiss pharmaceutical company known for its skin care treatments, has identified an opportunity in the growing trend of weight-loss drugs like Ozempic. The CEO believes that the popularity of these medications could lead to an increase in demand for their facial fillers products. This is because Ozempic can cause a sunken-in look in some patients’ faces, which fillers can help to counteract.
Galderma has been closely monitoring the rise of “Ozempic face,” a term used to describe the sunken and aged appearance that can result from rapid weight loss. To address this issue, the company has developed products like Sculptra that are designed to restore the gaunt look associated with Ozempic face. Galderma has also started a study to evaluate the effects of Sculptra and Restylane for cheek augmentation and contour deficiencies in patients using GLP-1 treatments. Enrollment is ongoing, and results may be available by the end of the year.
Dermatologists have also noted an increase in cases of “Ozempic face” due to the widespread use of weight-loss medications. They believe that as more people turn to these medications for weight loss, this trend will continue to grow.
Galderma went public last month on the SIX Swiss Exchange and reported a 12.4% increase in sales year-over-year in the first quarter of the year. In addition to its skin care treatments, Galderma also owns popular drug store brand Cetaphil. The CEO remains optimistic about the growth potential in the fillers market and plans to capitalize on this trend by expanding its product line and reaching out to more customers.
In conclusion, Galderma sees an opportunity in the growing trend of weight-loss drugs like Ozempic and is taking advantage of it by developing new facial filler products and conducting studies on their effectiveness. With more people turning to these medications for weight loss, it’s likely that this trend will continue to grow in the future.
